Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Abpro Holdings ( (ABP) ).
On November 4, 2025, Abpro Holdings and Celltrion announced they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the SITC 2025 Annual Meeting. The data highlights CT-P72/ABP-102’s potent anti-tumor activity, particularly in HER2-high models, including those resistant to current treatments, and supports its advancement toward clinical development. The antibody’s design aims to enhance tumor selectivity and safety, potentially setting a new standard in HER2-targeted immunotherapy.
The most recent analyst rating on (ABP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Abpro Holdings stock, see the ABP Stock Forecast page.
More about Abpro Holdings
Abpro Holdings is a biotechnology company focused on developing next-generation antibody therapies for severe and life-threatening diseases. The company is advancing treatments for HER2-positive cancers, non-HER2-positive gastric and liver cancer, and conditions like wet age-related macular degeneration and diabetic macular edema, using its proprietary DiversImmune® platform.
Average Trading Volume: 174,473
Technical Sentiment Signal: Sell
Current Market Cap: $14.26M
Find detailed analytics on ABP stock on TipRanks’ Stock Analysis page.